Disc Medicine (IRON) has shared an announcement.
Disc Medicine, Inc. has revealed promising results from its Phase 2 AURORA Study of the drug Bitopertin for patients with Erythropoietic Protoporphyria (EPP). The treatment showed significant reductions in the blood level of protoporphyrin IX and lessened phototoxic reactions with pain, although some endpoints did not show statistical significance due to unexpected placebo performance. The study involved 75 adults over 17 weeks and demonstrated that Bitopertin was generally well-tolerated. These findings could represent a significant advancement in EPP treatment, a condition that causes extreme sensitivity to sunlight, and the company anticipates further clinical developments.
Learn more about IRON stock on TipRanks’ Stock Analysis page.
